The global Intrauterine Contraceptive Devices (IUD) Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2029. Intrauterine Contraceptive Devices (IUD) are small T-shaped copper or plastic devices that are put into uterus (womb) by a nurse or a doctor. It protects against pregnancy for around 5-10 years. It is also referring as copper coil or coil. The Intrauterine Contraceptive Devices (IUD) market is expanding because of factors such as the rising technological initiatives towards effective contraception and increasing rate of unintended pregnancies.

According to World Health Organization (WHO) in 2019, adolescent aged 15-19 years across various middle and low income countries had around 21 million pregnancies every year. Among these about 50% were unintended and resulted in estimated 12 million births Whereas rising government and private firms initiatives towards unwanted pregnancies & growing awareness towards unwanted abortions create lucrative opportunities for the market. However, risk of causing pelvic inflammatory hampers the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Intrauterine Contraceptive Devices (IUD) Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the increasing adoption by women towards effective forms of reversible contraception, and growing interest by healthcare providers. Whereas North America is expected to grow significantly during the forecast period, owing to factors such as the presence of better healthcare infrastructure and growing awareness among population.


Major market players included in this report are:
Abbvie Inc (Allergan Plc)
Bayer AG
CooperSurgical Inc.
DKT International
EUROGINE, S.L
Mona Lisa NV
Pregna International Limited
Prosan International BV
SMB Corporation of India
Melbea AG

Recent Developments in the Market:
? In June 2021, Sebela Pharmaceuticals Inc. is conducting a phase III clinical trial with PRA Health Sciences to evaluate LevoCept, a long-acting reversible intrauterine system, for contraceptive efficacy, safety, and tolerability. The trial is scheduled to conclude in June 2027.
? In February 2020, Agile Therapeutics, Inc. received FDA approval for Twirla (levonorgestrel and ethinyl estradiol) transdermal system, which is indicated as a method of contraception for use in women of reproductive potential with a BMI of 30 kg/m2 who require a combined hormonal contraceptive.
Global Intrauterine Contraceptive Devices (IUD) Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, End-user, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
Hormonal Intrauterine Device,
Copper Intrauterine Device

By End-user:
Hospitals,
Gynecology Clinics
Community Health Care Centers

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World